Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study.

Authors

Alí Duarte-García, Marlon J Sandino-Bermúdez, Mariana González-Treviño, Cynthia S Crowson, Rozalina G McCoy, Yihong Deng

Published in

Arthritis & rheumatology (Hoboken, N.J.). Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Compare infection-related hospitalization risk among patients with non-renal SLE initiating commonly used immunosuppressants.
We emulated a target trial using Optum Labs Data Warehouse claims to compare the risk of infection-related hospitalization among patients initiating azathioprine, belimumab, methotrexate, or mycophenolic acid analogues (MPAA) between March 2011 and September 2023. We excluded patients with prior lupus nephritis, solid-organ or bone marrow transplantation, or rituximab/cyclophosphamide exposure. The primary outcome was time to first infection-related hospitalization, using intention-to-treat (ITT) and per-protocol (PP) analyses. We applied inverse probability of treatment weighting to account for baseline covariates and fitted marginal structural Cox models incorporating time-varying monthly glucocorticoid dose during follow-up.
Among 6,168 patients, 24-month cumulative incidence of infection-related hospitalization was 10% (95%CI 8-12) for azathioprine, 8% (95%CI 5-10) for belimumab, 10% (95%CI 8-11) for methotrexate, and 13% (95%CI 10-15) for MPAA. In ITT analyses, MPAA had higher risk than belimumab (HR 1.55; 95%CI 1.07-2.25) and methotrexate (HR 1.32; 95%CI 1.04-1.68). In PP analyses, azathioprine (HR 2.04; 95%CI 1.01-4.16) and MPAA (HR 2.27; 95%CI 1.11-4.62) had higher risk compared with belimumab. After accounting for time-varying monthly glucocorticoid dose, between-treatment differences were no longer significant.
Initial differences in the infection-related hospitalization risk were attenuated after accounting for time-varying glucocorticoid exposure. These findings highlight glucocorticoid exposure as an important factor associated with serious infection risk, while recognizing that post-baseline glucocorticoid use may reflect both evolving disease activity and a pathway through which therapies influence infection risk.

PMID:
42750573
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.